STOCKWATCH
·
Medical/Dental Instruments
Quarterly ResultApr 30, 2026, 04:05 PM

IRTC Q1 Revenue +25.7% to $199.4M; Net Loss Improves; FY26 Guidance Raised

AI Summary

iRhythm Holdings reported strong first-quarter 2026 financial results, with revenue increasing 25.7% to $199.4 million and gross margin expanding to 70.9%. The company significantly improved its net loss to $13.9 million and achieved positive adjusted EBITDA of $14.1 million. iRhythm also raised its fiscal year 2026 revenue guidance to $875 million-$885 million and adjusted EBITDA margin to 12.0%-13.0%, driven by robust volume growth and operational efficiencies.

Key Highlights

  • Q1 2026 revenue increased 25.7% to $199.4 million from $158.7 million in Q1 2025.
  • Gross margin improved by 210 basis points to 70.9% in Q1 2026.
  • Net loss improved by $16.8 million to $13.9 million in Q1 2026.
  • Adjusted EBITDA was $14.1 million, an $16.7 million improvement YoY.
  • Unrestricted cash, cash equivalents, and marketable securities totaled $549.6 million.
  • Fiscal year 2026 revenue guidance raised to $875 million to $885 million.
  • Fiscal year 2026 adjusted EBITDA margin guidance raised to 12.0% to 13.0%.
IRTC
Medical/Dental Instruments
iRhythm Holdings, Inc.

Price Impact